Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Translation in Brief

Targeting pathogenic Th17 cells

How two new autoimmune targets drive pathogenic Th17 activity

Michael Leviten, Senior Writer
March 1, 2019 1:48 AM UTC

A recent pair of studies offers two new approaches to treating autoimmune diseases that go after the source of Th17-mediated inflammation.

T helper type 17 (Th17) cells are effector T cells that secrete the cytokine IL-17. Normal Th17 activity is required for host defense against pathogens, but hyperactivity leads to autoimmune disorders such as multiple sclerosis, psoriasis and rheumatoid arthritis. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

AutoImmune Inc.